Paul D. Rubin
CIK: 0001210905
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BioAge Labs, Inc.
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Apr 1, 2026BIOA
BioAge Labs, Inc.
Exercise(M)Direct3.4K shares at avg. $6.57$22K - Apr 1, 2026BIOA
BioAge Labs, Inc.
Sale(S)Direct8.8K shares at avg. $17.81$157K - Apr 1, 2026BIOA
BioAge Labs, Inc.
Exercise(M)Direct5.4K shares at avg. $4.11$22K - Mar 2, 2026BIOA
BioAge Labs, Inc.
Exercise(M)Direct2K shares at avg. $6.57$13K - Mar 2, 2026BIOA
BioAge Labs, Inc.
Sale(S)Direct7.4K shares at avg. $20.30$151K - Mar 2, 2026BIOA
BioAge Labs, Inc.
Exercise(M)Direct5.4K shares at avg. $4.11$22K - Feb 17, 2026BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
110K shares- - Feb 2, 2026BIOA
BioAge Labs, Inc.
Sale(S)Direct7.4K shares at avg. $18.75$139K - Feb 2, 2026BIOA
BioAge Labs, Inc.
Exercise(M)Direct5.4K shares at avg. $4.11$22K - Feb 2, 2026BIOA
BioAge Labs, Inc.
Exercise(M)Direct2K shares at avg. $6.57$13K - Jan 2, 2026BIOA
BioAge Labs, Inc.
Exercise(M)Direct5.4K shares at avg. $4.11$22K - Jan 2, 2026BIOA
BioAge Labs, Inc.
Sale(S)Direct7.4K shares at avg. $12.85$95K - Jan 2, 2026BIOA
BioAge Labs, Inc.
Exercise(M)Direct2K shares at avg. $6.57$13K - Dec 9, 2025BIOA
BioAge Labs, Inc.
Sale(S)Direct18K shares at avg. $12.00$216K - Dec 9, 2025BIOA
BioAge Labs, Inc.
Exercise(M)Direct18K shares at avg. $6.57$118K - Dec 4, 2025BIOA
BioAge Labs, Inc.
Sale(S)Direct68.9K shares at avg. $10.19$702K - Dec 4, 2025BIOA
BioAge Labs, Inc.
Exercise(M)Direct68.9K shares at avg. $4.11$283K - Feb 18, 2025BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
200K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | Exercise(M) | 3,383 | $6.57 | $22,226 | Direct |
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | Sale(S) | 8,820 | $17.81 | $157,084 | Direct |
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | Exercise(M) | 5,437 | $4.11 | $22,346 | Direct |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | Exercise(M) | 2,000 | $6.57 | $13,140 | Direct |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | Sale(S) | 7,433 | $20.30 | $150,890 | Direct |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | Exercise(M) | 5,433 | $4.11 | $22,330 | Direct |
| Feb 17, 2026 | BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 110,000 | - | - | Direct |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | Sale(S) | 7,433 | $18.75 | $139,369 | Direct |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | Exercise(M) | 5,433 | $4.11 | $22,330 | Direct |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | Exercise(M) | 2,000 | $6.57 | $13,140 | Direct |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | Exercise(M) | 5,433 | $4.11 | $22,330 | Direct |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | Sale(S) | 7,433 | $12.85 | $95,490 | Direct |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | Exercise(M) | 2,000 | $6.57 | $13,140 | Direct |
| Dec 9, 2025 | BIOA BioAge Labs, Inc. | Sale(S) | 18,000 | $12.00 | $216,000 | Direct |
| Dec 9, 2025 | BIOA BioAge Labs, Inc. | Exercise(M) | 18,000 | $6.57 | $118,260 | Direct |
| Dec 4, 2025 | BIOA BioAge Labs, Inc. | Sale(S) | 68,897 | $10.19 | $701,909 | Direct |
| Dec 4, 2025 | BIOA BioAge Labs, Inc. | Exercise(M) | 68,897 | $4.11 | $283,167 | Direct |
| Feb 18, 2025 | BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 200,000 | - | - | Direct |
1-18 of 18 transactions
About RUBIN PAUL D
RUBIN PAUL D (SEC CIK 0001210905) files insider reports with the SEC as Chief Medical Officer of BioAge Labs, Inc. (BIOA).
Signal8 holds 9 ownership filings by RUBIN PAUL D (1 Form 3, 8 Form 4), filed between Sep 25, 2024 and Apr 3, 2026. Those filings report 18 transactions, from Feb 18, 2025 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on RUBIN PAUL D's filings is in EMERYVILLE, CA.
Recent filings by RUBIN PAUL D
- Apr 1, 2026: Option exercise of BIOA shares (Form 4, code M).
- Apr 1, 2026: Open-market sale of BIOA shares (Form 4, code S).
- Apr 1, 2026: Option exercise of BIOA shares (Form 4, code M).
- Mar 2, 2026: Option exercise of BIOA shares (Form 4, code M).
- Mar 2, 2026: Open-market sale of BIOA shares (Form 4, code S).
Other insiders filing for BioAge Labs, Inc. (BIOA)
- Barton Shane, Principal Accounting Officer
- Pande Vijay Satyanand, Director
- Hemrajani Rekha, Director
- HEALY JAMES, Director
- ENRIGHT PATRICK G, Director
- Davidson Michael H., Director